These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24636833)

  • 1. The pros and cons of lamivudine vs. entecavir in decompensated or severe acute exacerbation of chronic hepatitis B.
    Shouval D
    J Hepatol; 2014 Jun; 60(6):1108-9. PubMed ID: 24636833
    [No Abstract]   [Full Text] [Related]  

  • 2. Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation.
    Chen CH; Lin CL; Hu TH; Hung CH; Tseng PL; Wang JH; Chang JY; Lu SN; Chien RN; Lee CM
    J Hepatol; 2014 Jun; 60(6):1127-34. PubMed ID: 24583247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine improves short-term outcome in hepatitis B virus-related acute-on-chronic liver failure patients with a high model for end-stage liver disease score.
    Li X; Gao F; Liu H; Zhang H; Liu Y; Ye X; Geng M; Sun L; Wang R; Li Y; Jiang Y; Wang X; Zhou G; Yang Z; Li A; Zeng H; Wang X
    Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):1-9. PubMed ID: 27749778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of entecavir in preventing hepatitis B recurrence after liver transplantation.
    Xi ZF; Xia Q; Zhang JJ; Chen XS; Han LZ; Wang X; Shen CH; Luo Y; Xin TY; Wang SY; Qiu DK
    J Dig Dis; 2009 Nov; 10(4):321-7. PubMed ID: 19906113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.
    Suzuki F; Akuta N; Suzuki Y; Yatsuji H; Sezaki H; Arase Y; Kawamura Y; Hosaka T; Kobayashi M; Ikeda K; Kobayashi M; Watahiki S; Kumada H
    J Clin Virol; 2007 Jun; 39(2):149-52. PubMed ID: 17442615
    [No Abstract]   [Full Text] [Related]  

  • 7. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW; Coyle L; Jones BE; Pattullo V
    Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenofovir, entecavir, and lamivudine in patients with severe acute exacerbation and hepatic decompensation of chronic hepatitis B.
    Park JG; Lee YR; Park SY; Lee HJ; Tak WY; Kweon YO; Jang SY; Chun JM; Han YS; Hur K; Lee HW; Kang MK
    Dig Liver Dis; 2018 Feb; 50(2):163-167. PubMed ID: 29089265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Lamivudine Versus Entecavir for Treating Chronic Hepatitis B Virus-related Acute Exacerbation and Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis.
    Huang KW; Tam KW; Luo JC; Kuan YC
    J Clin Gastroenterol; 2017 Jul; 51(6):539-547. PubMed ID: 28067752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside/nucleotide analogues.
    Lim YS; Lee TH; Heo NY; Shim JH; Lee HC; Suh DJ
    Antivir Ther; 2012; 17(1):53-60. PubMed ID: 22267469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
    Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
    Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
    Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
    Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B.
    Wong VW; Wong GL; Yiu KK; Chim AM; Chu SH; Chan HY; Sung JJ; Chan HL
    J Hepatol; 2011 Feb; 54(2):236-42. PubMed ID: 21030105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the therapeutical effects of entecavir and lamvudine in treatment of HBeAg-positive chronic hepatitis B].
    Hou HB; Deng LN; Li CP; Liu XR; Liu FQ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):873-4. PubMed ID: 19958652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.